-

09:18:24 AM

KYMR Stock News

KYMR - Kymera Therapeutics Inc

10/20/21 8:00 AM

Nasdaq : KYMR

clinical trial

Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will hold a webcast

RHEA-AI

neutral

10/13/21 7:00 AM

Nasdaq : KYMR

conferencesclinical trial

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will be giving

RHEA-AI

neutral

09/02/21 8:00 AM

Nasdaq : KYMR

conferences

Kymera Therapeutics to Present at Upcoming September Investor Conferences

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two

RHEA-AI

neutral

08/06/21 7:00 AM

Nasdaq : KYMR

earnings

Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update

Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism Recently initiated dosing of healthy volunteers in the Multiple Ascending Dose portion of Phase 1 trial of KT-474 Expect Investigational

RHEA-AI

neutral

07/29/21 7:00 AM

Nasdaq : KYMR

management

Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Karen Weisbach, as Vice

RHEA-AI

neutral

07/12/21 8:00 AM

Nasdaq : KYMR

clinical trial

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum

Data demonstrate Kymera’s ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma subtypes with aberrant STAT3 activation Kymera anticipates IND submission for STAT3 degrader KT-333 in

RHEA-AI

neutral

07/06/21 4:00 PM

Nasdaq : KYMR

offering

Kymera Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the closing of its upsized underwritten

RHEA-AI

neutral

06/30/21 9:45 PM

Nasdaq : KYMR

offering

Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the pricing of its upsized underwritten

RHEA-AI

neutral

06/28/21 4:36 PM

Nasdaq : KYMR

offering

Kymera Therapeutics Announces Proposed Public Offering of Common Stock

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that it has commenced an underwritten public

RHEA-AI

neutral

06/28/21 6:00 AM

Nasdaq : KYMR

clinical trial

Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism

KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with 90% median degradation at the 300 mg dose After single dose administration, degradation was maintained for at least six days at all dose levels, with no

RHEA-AI

neutral

KYMR Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.kymeratx.com
Security nameKymera Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees75
Tags
- Health Technology
- Biotechnology

KYMR Description:

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.